Windlas Biotech Ltd. (WINDLAS) Price & Analysis

Compare

0 Followers

WINDLAS Stock Chart & Stats

₹788.05

₹26.85(2.61%)

At close: Jan 08 4:00 PM EST

₹788.05

₹26.85(2.61%)

Day’s Range― - ―

52-Week Range₹728.15 - ₹1,137.60

Previous CloseN/A

Volume34.51K

Average Volume (3M)3.48K

Market Cap

₹15.95B

Enterprise Value₹16.22B

Total Cash (Recent Filing)₹2.39B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)27.9

Beta0.97

Next Earnings

May 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.71%

Share Statistics

EPS (TTM)7.12

Shares Outstanding21,136,883

10 Day Avg. Volume3,282

30 Day Avg. Volume3,478

Financial Highlights & Ratios

PEG Ratio8.12

Price to Book (P/B)4.20

Price to Sales (P/S)2.80

P/FCF Ratio132.80

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue & Margin ImprovementSustained revenue growth alongside rising gross and EBITDA margins indicates durable demand and improving cost control. Persistent margin expansion supports stronger operating cash generation and reinvestment capacity, underpinning long-term profitability and competitive resilience.

Healthy Balance SheetA conservative leverage profile and strong equity base reduce financial risk and enhance flexibility to fund capex, acquisitions, or weather cyclicality. Low debt levels lower interest burden and provide durable optionality for strategic investments over the next several quarters.

Diversified Revenue StreamsMultiple channels—branded and generic formulations, OTC and contract manufacturing—lower customer and product concentration risk. Contract manufacturing provides steady utilization and recurring revenue, supporting long-term cash flow stability and scale benefits in production.

Bears Say

Operating Cash Flow DeclineA year-over-year decline in operating cash flow weakens internal funding for working capital and growth initiatives. Even with positive net income, weaker cash conversion can constrain capex or M&A options and may require more prudent liquidity management over coming quarters.

Volatile Free Cash Flow GrowthFluctuating free cash flow limits the firm's ability to commit to consistent returns or expansion plans. Volatility increases planning uncertainty for investments, dividends or debt reduction and raises the need for larger cash buffers or external financing in adverse periods.

Rising Total Liabilities To MonitorAlthough leverage is low today, an uptick in total liabilities could signal emerging funding needs or increased payables. If the trend continues it could erode financial flexibility and raise credit or refinancing risks, reducing capacity for strategic spending over time.

Windlas Biotech Ltd. News

Windlas Biotech Schedules Investor and Analyst Meetings for December 2025

Windlas Biotech Ltd. ( ($IN:WINDLAS) ) just unveiled an announcement. Windlas Biotech Ltd. announced its schedule for upcoming...

3M ago

Windlas Biotech Updates Employee Stock Unit Grant Plan

Windlas Biotech Ltd. ( ($IN:WINDLAS) ) has issued an update. Windlas Biotech Limited has announced amendments to Sub-clause...

6M ago

Windlas Biotech Clarifies Stock Unit Grant Limits in ‘Windlas Plan 2025’

The latest announcement is out from Windlas Biotech Ltd. ( ($IN:WINDLAS) ). Windlas Biotech Limited announced the approval...

6M ago

Windlas Biotech Completes Dispatch of Annual Report and AGM Notice

Windlas Biotech Ltd. ( ($IN:WINDLAS) ) has issued an update. Windlas Biotech Limited has announced the completion of...

8M ago

Windlas Biotech Schedules Investor Meeting to Enhance Stakeholder Engagement

Windlas Biotech Ltd. ( ($IN:WINDLAS) ) has issued an update. Windlas Biotech Ltd. has announced a scheduled meeting...

12M ago

Windlas Biotech Schedules Investor Meeting at Dehradun Facility

Windlas Biotech Ltd. ( ($IN:WINDLAS) ) has shared an update. Windlas Biotech Ltd. has announced a scheduled meeting...

12M ago

WINDLAS FAQ

What was Windlas Biotech Ltd.’s price range in the past 12 months?

Windlas Biotech Ltd. lowest stock price was ₹728.15 and its highest was ₹1137.60 in the past 12 months.

What is Windlas Biotech Ltd.’s market cap?

Windlas Biotech Ltd.’s market cap is ₹15.95B.

When is Windlas Biotech Ltd.’s upcoming earnings report date?

Windlas Biotech Ltd.’s upcoming earnings report date is May 27, 2026 which is in 82 days.

How were Windlas Biotech Ltd.’s earnings last quarter?

Windlas Biotech Ltd. released its earnings results on Feb 05, 2026. The company reported ₹7.118 earnings per share for the quarter, beating the consensus estimate of N/A by ₹7.118.

Is Windlas Biotech Ltd. overvalued?

According to Wall Street analysts Windlas Biotech Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Windlas Biotech Ltd. pay dividends?

Windlas Biotech Ltd. pays a Annually dividend of ₹5.8 which represents an annual dividend yield of 0.71%. See more information on Windlas Biotech Ltd. dividends here

What is Windlas Biotech Ltd.’s EPS estimate?

Windlas Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Windlas Biotech Ltd. have?

Windlas Biotech Ltd. has 21,136,883 shares outstanding.

What happened to Windlas Biotech Ltd.’s price movement after its last earnings report?

Windlas Biotech Ltd. reported an EPS of ₹7.118 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.123%.

Which hedge fund is a major shareholder of Windlas Biotech Ltd.?

Currently, no hedge funds are holding shares in IN:WINDLAS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Windlas Biotech Ltd.

Windlas Biotech Limited operates as a contract development and manufacturing organization (CDMO). Its CDMO services include product discovery, product development, licensing, and commercial manufacturing generic products, including generic products. The company provides its CMDO products and services across a range of pharmaceutical and nutraceutical conventional, and novel products for customers who market such products under their own brand names to the end users. It also offers manufactures various domestic trade generics and over-the-counter brand product portfolio to cater to nutritional, ayurvedic, wellness, and personal care markets. The company's domestic trade generics and OTC brands products are distributed through the offline channel, such as distributors, stockists, retail pharmacies, and institutional tenders, as well as the online channel, such as various e-commerce platforms. It exports its products primarily to Vietnam, Myanmar, Sri Lanka, Thailand, the Philippines, Cambodia, Fiji, Trinidad & Tobago, and South Africa. The company was incorporated in 2001 and is based in Gurugram, India.